Goldman Sachs
ESLA icon

Goldman Sachs’s Estrella Immunopharma ESLA Stock Holding History

Goldman Sachs’s Portfolio ESLA Stock Details ESLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-96,513
Closed -$971K – 6056
2022
Q3 		$971K Sell
96,513
-10,070
-9% -$101K ﹤0.01% 4530
2022
Q2 		$1.07M Hold
106,583
– – ﹤0.01% 4563
2022
Q1 		$1.06M Hold
106,583
– – ﹤0.01% 4773
2021
Q4 		$1.06M Hold
106,583
– – ﹤0.01% 4797
2021
Q3 		$1.05M Buy
+106,583
New +$1.05M ﹤0.01% 4698

Other funds holding ESLA

KIM
Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return
HHGC
Hunting Hill Global Capital New York $129M AUM 17.34% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
SIA
SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return
LCM
Landscape Capital Management Englewood, New Jersey $1.58B AUM 26.88% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
MC
Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Goldman Sachs's ESLA Position: Q4 2022 in Review

Goldman Sachs sold out of Estrella Immunopharma (ESLA) in Q4 2022, closing a stake of 96,513 shares — an estimated $971K sold.

Goldman Sachs first reported a position in ESLA in Q3 2021 and held it in 5 quarters. The position peaked at $1.07M in Q2 2022. 13 funds tracked by Wall St. Rank hold ESLA as of Q4 2022.

  • Goldman Sachs reported no remaining Estrella Immunopharma position as of Q4 2022 after selling out during the quarter.
  • Goldman Sachs sold 96,513 Estrella Immunopharma shares in Q4 2022, an estimated $971K.
  • Goldman Sachs first reported a position in Estrella Immunopharma in Q3 2021 and held it in 5 quarters.
  • Goldman Sachs's Estrella Immunopharma position peaked at $1.07M in Q2 2022.
  • 13 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q4 2022.

Based on Goldman Sachs's 13F filing for Q4 2022, filed 13 Feb 2023.